Wall Street brokerages forecast that NewLink Genetics Corp (NASDAQ:NLNK) will post earnings per share of ($0.55) for the current quarter, Zacks reports. Three analysts have issued estimates for NewLink Genetics’ earnings, with estimates ranging from ($0.66) to ($0.46). NewLink Genetics posted earnings of ($0.72) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 23.6%. The firm is expected to report its next quarterly earnings report on Thursday, May 3rd.
According to Zacks, analysts expect that NewLink Genetics will report full year earnings of ($2.35) per share for the current fiscal year, with EPS estimates ranging from ($2.67) to ($1.90). For the next fiscal year, analysts anticipate that the firm will report earnings of ($2.54) per share, with EPS estimates ranging from ($2.93) to ($1.76). Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that cover NewLink Genetics.
Several research firms have recently weighed in on NLNK. Bank of America lowered their price objective on shares of NewLink Genetics from $22.00 to $18.00 and set a “buy” rating on the stock in a research report on Friday, March 2nd. Cantor Fitzgerald set a $26.00 price objective on shares of NewLink Genetics and gave the company a “buy” rating in a research report on Friday, March 2nd. Zacks Investment Research upgraded shares of NewLink Genetics from a “hold” rating to a “buy” rating and set a $9.00 target price on the stock in a research report on Wednesday, January 3rd. BidaskClub upgraded shares of NewLink Genetics from a “sell” rating to a “hold” rating in a research report on Friday, January 5th. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $21.00 target price (down previously from $25.00) on shares of NewLink Genetics in a research report on Friday, March 2nd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $21.57.
Large investors have recently modified their holdings of the stock. Zurcher Kantonalbank Zurich Cantonalbank raised its position in NewLink Genetics by 1,823.0% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,269 shares of the biotechnology company’s stock worth $105,000 after purchasing an additional 9,735 shares during the period. Oppenheimer & Co. Inc. purchased a new position in NewLink Genetics in the 3rd quarter worth $114,000. Raymond James Financial Services Advisors Inc. purchased a new position in NewLink Genetics in the 4th quarter worth $118,000. Creative Planning purchased a new position in NewLink Genetics in the 4th quarter worth $152,000. Finally, The Manufacturers Life Insurance Company raised its position in NewLink Genetics by 3.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,069 shares of the biotechnology company’s stock worth $140,000 after purchasing an additional 556 shares during the period. Institutional investors own 65.14% of the company’s stock.
NewLink Genetics Company Profile
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.